Our top pick for
Beginners

Anchiano Therapeutics Ltd is a biotechnology business based in the US. Anchiano Therapeutics shares (ANCN) are listed on the NASDAQ and all prices are listed in US Dollars. Anchiano Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $61.36 |
200-day moving average | $34.74 |
Wall St. target price | $1.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-5.21 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -52.84% |
Return on equity TTM | -125.6% |
Profit margin | 0% |
Book value | $7.71 |
Market capitalisation | $34.9 million |
TTM: trailing 12 months
We're not expecting Anchiano Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Anchiano Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anchiano Therapeutics's is 0.9598. This would suggest that Anchiano Therapeutics's shares are less volatile than average (for this exchange).
Anchiano Therapeutics Ltd. , a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.